TY - JOUR
T1 - Progress report on new antiepileptic drugs
T2 - A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development
AU - Bialer, Meir
AU - Johannessen, Svein I.
AU - Koepp, Matthias J.
AU - Levy, René H.
AU - Perucca, Emilio
AU - Perucca, Piero
AU - Tomson, Torbjörn
AU - White, H. Steve
N1 - Publisher Copyright:
© 2022 International League Against Epilepsy.
PY - 2022/11
Y1 - 2022/11
N2 - The Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI) was held in Madrid, Spain on May 22–25, 2022 and was attended by 157 delegates from 26 countries representing basic and clinical science, regulatory agencies, and pharmaceutical industries. One day of the conference was dedicated to sessions presenting and discussing investigational compounds under development for the treatment of seizures and epilepsy. The current progress report summarizes recent findings and current knowledge for seven of these compounds in more advanced clinical development for which either novel preclinical or patient data are available. These compounds include bumetanide and its derivatives, darigabat, ganaxolone, lorcaserin, soticlestat, STK-001, and XEN1101. Of these, ganaxolone was approved by the US Food and Drug Administration in March 2022 for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients 2 years of age and older.
AB - The Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI) was held in Madrid, Spain on May 22–25, 2022 and was attended by 157 delegates from 26 countries representing basic and clinical science, regulatory agencies, and pharmaceutical industries. One day of the conference was dedicated to sessions presenting and discussing investigational compounds under development for the treatment of seizures and epilepsy. The current progress report summarizes recent findings and current knowledge for seven of these compounds in more advanced clinical development for which either novel preclinical or patient data are available. These compounds include bumetanide and its derivatives, darigabat, ganaxolone, lorcaserin, soticlestat, STK-001, and XEN1101. Of these, ganaxolone was approved by the US Food and Drug Administration in March 2022 for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients 2 years of age and older.
KW - antiepileptic drugs
KW - antiseizure medications
KW - drug development
KW - epilepsy
UR - http://www.scopus.com/inward/record.url?scp=85135844608&partnerID=8YFLogxK
U2 - 10.1111/epi.17376
DO - 10.1111/epi.17376
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35950617
AN - SCOPUS:85135844608
SN - 0013-9580
VL - 63
SP - 2883
EP - 2910
JO - Epilepsia
JF - Epilepsia
IS - 11
ER -